Lantern Pharma has entered a strategic AI-driven collaboration with French biotechnology company Oregon Therapeutics to optimise the development of its first-in-class protein disulfide isomerase (PDI)1 inhibitor drug candidate XCE853 in novel and targeted cancer indications. Lantern will be leveraging its RADR AI platform to uncover biomarkers and efficacy-associated signatures of XCE853 across solid tumours that can aid in […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!